India's Piramal Enterprises says gets U.S. nod for new drug trials

Tue Aug 6, 2013 2:39am EDT

Aug 6 (Reuters) - India's Piramal Enterprises Ltd said it has received U.S. regulatory approval to initiate phase I clinical trials for its new drug indicated for lowering lipid and diabetes treatment.

The P7435 molecule has shown significant reduction in triglycerides, blood glucose and insulin levels in pre-clinical studies, the company said in a statement on Tuesday. Its phase I trials will start soon in the United States, it said.